ALX Oncology Holdings Inc. Common Stock (ALXO)
PHARMACEUTICAL PREPARATIONS
ALX Oncology Holdings Inc. Common Stock (ALXO) is listed on Nasdaq, where it has traded since July 17, 2020.
- Listed On
- Nasdaq
- Listed Since
- July 17, 2020
- Employees
- 48
- Market Cap
- $181M
About ALX Oncology Holdings Inc. Common Stock
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 91 institutions reported holding ALXO, with 105.2 million shares worth $217.9 million in aggregate. The largest reported holder was RA Capital Management,, with 13.0 million shares worth $26.9 million. Of the 5 largest holders listed below, 2 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| RA Capital Management, | 13,011,849 | $27M | Unchanged |
| Venbio Partners | 12,884,638 | $27M | Unchanged |
| BlackRock | 7,399,530 | $15M | Added 1552.42% |
| Redmile Group | 7,392,504 | $15M | Reduced 7.18% |
| Blackstone | 6,593,543 | $14M | Added 13.16% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ALXO?
ALX Oncology Holdings Inc. Common Stock (ALXO) is listed on Nasdaq, where it has traded since July 17, 2020.
Who are the largest institutional holders of ALXO?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ALXO were RA Capital Management,, Venbio Partners and BlackRock.
How many institutions own ALXO?
91 institutions reported a position in ALXO for the quarter ended June 30, 2026, worth $217.9 million in total.
Did institutions buy or sell ALXO last quarter?
Of the 5 largest reported holders, 2 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for ALXO.
Every reported institutional holder, plus insider and congressional trades in ALXO, on SentiSense.